Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs Dollar General Corp. (DG) Price & Performance

Abbott LaboratoriesTrade
Dollar General Corp.Trade

Price performance (Past 24H)

Key statistics

Abbott Laboratories vs Dollar General Corp. — how do they compare? Abbott Laboratories trades at $109.4 (market cap $187.95B), while Dollar General Corp. trades at $120.33 (market cap $26.49B). The key difference: Abbott Laboratories is far larger — about 7.1× Dollar General Corp.'s market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.

ABTDG
Market Cap
$187.95B$26.49B
Sector
HealthConsumer Staples
52-Week High
$136.62$156.26
52-Week Low
$82.57$95.94
Enterprise Value
$214.96B$40.93B
Dividend Yield
2.32%1.97%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.

Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.

Dollar General Corp.

Dollar General (DG) trades at $122.39, down 3.32% on the day, with a bearish technical signal. The stock shows strong fundamentals with a P/E of 16.98 and P/S of 0.62, indicating potential undervaluation. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $2.00 surpassing the $1.89 expectation. Positive cash flow trends and a declining debt-to-asset ratio (20.03 in 2025) support financial health. A dividend of $0.59 is scheduled for payment on July 21, 2026.

The outlook is cautiously optimistic, with a consensus price target of $128.45 offering ~5% upside. Analyst sentiment is bullish (52% Buy ratings), but risks include competitive pressure from Walmart and Amazon, margin compression from rising costs, and market saturation. Revenue growth is projected to reach $43.1B in 2026, though net margin remains thin at 3.63%.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About Dollar General Corp.

A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.

Read more on DG